Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
Here's Simulations Plus Inc (SLP)'s Vision for AI in Drug Development [Yahoo! Finance]
Simulations Plus: Better Quarter, Same Doubts [Seeking Alpha]
Simulations Plus (SLP) had its price target lowered by TD Cowen from $19.00 to $16.00. They now have a "hold" rating on the stock.